Gedeon Richter Partnering Partnering in General Medicines
Partnering in General Medicines
The General Medicines (GenMed) Business Unit focuses on the development, licensing and commercialization of generic and value‑added medicines across Europe and the Commonwealth of Independent States (CIS). Our strategy is to build a high-quality, sustainable portfolio addressing major unmet needs within established therapeutic areas, supported by strong development, regulatory and commercialization capabilities in our core regions.
Strategic indications

We actively focus on the following therapeutic segments: 

  • Cardiology 
  • Diabetes 
  • Obesity 
  • Neurology 

Within these areas, we are particularly interested in:

  • differentiated and complex generics 
  • fixed-dose combinations 
  • reformulations and lifecycle management opportunities 
  • products with clear medical, adherence or market access advantages 

Development & Regulatory Capabilities 

Our integrated development organization covers: 

  • generic and value-added product development, including complex formulations 
  • bioequivalence and clinical development programs, where required 
  • regulatory strategy and submissions across EU, CEE and CIS markets 
  • lifecycle management and dossier optimization 

We have strong expertise in managing multi-jurisdictional regulatory pathways, enabling efficient and coordinated market access across our core territories. 

Manufacturing & Supply Chain 

We rely on: 

  • a robust internal manufacturing network, complemented by external partners 
  • proven capabilities in technology transfer and industrial scale-up 
  • efficient and flexible supply chain solutions tailored to multi-market distribution 

Commercial & Market Access Capabilities

GenMed benefits from: 

  • a well-established commercial infrastructure in Europe and CIS
  • strong presence in key therapeutic areas 
  • deep understanding of pricing, reimbursement and local access dynamics 

We provide end-to-end commercialization support, including: 

  • regulatory execution 
  • market access strategy and pricing 
  • commercial launch and lifecycle management 
 
 

Partnering Approach

Our collaboration model is characterized by:

  • flexibility in deal structures 
  • transparent governance and joint decision-making
  • strong focus on efficient execution and time-to-market

We aim to build long-term, value-driven partnerships that combine:

  • complementary capabilities
  • shared development risks
  • aligned commercial interests

Mr Mihaly Majnar

Manager of Business Development, General Medicines Unit

M.Majnar @ richter.hu